Skip to main content
Back
NPPNY logo

Nippon Shinyaku Co., Ltd.

Data quality: 100%
NPPNY
OTC Healthcare Drug Manufacturers - Specialty & Generic
$8.07
▼ $0.39 (-4.56%)
Mkt Cap: 2.17B
Also listed as NPNKF OTC
Day Range
$8.07 $8.71
52-Week Range
$5.03 $15.21
Volume
1
50D / 200D Avg
$8.65 / $6.75
Prev Close
$8.45

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E 0.1 0.4
P/B 0.0 2.9
ROE % 13.9 3.7
Net Margin % 20.3 3.8
Rev Growth 5Y % 7.1 10.0
D/E 0.0 0.2

Key Takeaways

Revenue grew 7.08% annually over 5 years — modest growth
Earnings grew 25.94% over the past year
ROE of 13.94% — decent returns on equity
Net margin of 20.32% shows strong profitability
Debt/Equity of 0.01 — conservative balance sheet
Generating 32.77B in free cash flow

Growth

Revenue Growth (5Y)
7.08%
Revenue (1Y)8.08%
Earnings (1Y)25.94%
FCF Growth (3Y)50.64%

Quality

Return on Equity
13.94%
ROIC11.04%
Net Margin20.32%
Op. Margin22.94%

Safety

Debt / Equity
0.01
Current Ratio4.94
Interest Coverage253.54

Valuation

P/E Ratio
0.07
P/B Ratio0.01
EV/EBITDA-1.37
Dividend Yield0.03%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 8.08% Revenue Growth (3Y) 5.42%
Earnings Growth (1Y) 25.94% Earnings Growth (3Y) 19.47%
Revenue Growth (5Y) 7.08% Earnings Growth (5Y) 13.61%
Profitability
Revenue (TTM) 160.23B Net Income (TTM) 32.56B
ROE 13.94% ROA 11.48%
Gross Margin 68.10% Operating Margin 22.94%
Net Margin 20.32% Free Cash Flow (TTM) 32.77B
ROIC 11.04% FCF Growth (3Y) 50.64%
Safety
Debt / Equity 0.01 Current Ratio 4.94
Interest Coverage 253.54 Dividend Yield 0.03%
Valuation
P/E Ratio 0.07 P/B Ratio 0.01
P/S Ratio 0.01 PEG Ratio 0.30
EV/EBITDA -1.37 Dividend Yield 0.03%
Market Cap 2.17B Enterprise Value -50.34B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 160.23B 148.26B 144.18B 137.48B 121.89B
Net Income 32.56B 25.85B 22.81B 24.99B 19.54B
EPS (Diluted) 120.82 95.96 84.68 92.74 72.53
Gross Profit 109.12B 97.02B 88.20B 87.29B 71.93B
Operating Income 36.76B 31.39B 30.05B 32.95B 26.13B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 283.64B 263.40B 237.45B 219.94B 197.03B
Total Liabilities 36.30B 42.87B 41.52B 39.06B 34.49B
Shareholders' Equity 247.03B 220.22B 195.62B 180.58B 162.25B
Total Debt 2.72B 2.87B 2.66B 2.71B 2.84B
Cash & Equivalents 55.24B 58.09B 60.05B 60.57B 47.77B
Current Assets 149.74B 164.29B 157.87B 149.72B 139.09B
Current Liabilities 30.32B 37.34B 35.18B 32.03B 31.51B

Strategy Scores

This stock passed the criteria for 3 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#493 of 1024
46
Custom Deep Value Investing (Seth Klarman)
#533 of 820
35
Value Defensive Investing (Benjamin Graham)
#668 of 708
3

Recent Activity

Entered Cash Flow Compounder
Mar 24, 2026
Entered Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entered Defensive Investing (Benjamin Graham)
Mar 24, 2026